How Healthcare IT Companies Are Actually Valued
Healthcare IT is not a single market — it's at least five distinct sub-segments that trade on completely different multiples and to completely different buyers. Lumping EMR vendors, RCM platforms, care-coordination tools, clinical-decision-support, and payer-tech into one "HIT" bucket is the fastest way to mis-price a transaction. Below is how I actually triangulate what a company is worth.
Sub-Segment Drives Almost Everything
EMR / EHR platforms (Athena, eClinicalWorks, Greenway, Practice Fusion-style): These trade as sticky, mission-critical infrastructure. Switching costs are enormous, gross retention sits in the high 90s, but growth is mature. Public comps are limited — Athenahealth went private at ~$17B (Bain / Veritas, 2022) and Cerner sold to Oracle for $28B in 2022 at roughly a revenue multiple. Mid-market EMR platforms trade a revenue-multiple range, premium leaders 10-14x.
Revenue Cycle Management (Athenahealth's RCM arm, R1 RCM, Privia-style platforms): RCM trades on a blend of revenue and EBITDA. The economics are services-heavy with software wrapping — so multiples sit lower than pure SaaS, typically a revenue-multiple range or platform-tier earnings multiples. Outsourced RCM with high-margin tech leverage gets to the higher end; people-heavy BPO-style RCM trades closer to staffing-business multiples (platform-tier earnings multiples).
Care coordination and population health (Innovaccer, Bamboo Health, Arcadia): This is where the premium multiples live. Innovaccer raised at a $3.4B valuation. Bamboo Health sold to Kohlberg & Company in 2023. These platforms trade a revenue-multiple range if they have payer distribution and a revenue-multiple range if they're still proving the channel.
Clinical decision support and life-sciences tech (Veeva, Doximity, Omnicell): Veeva (VEEV) trades around a revenue-multiple range and ~an earnings multiple on the public markets — it's the anchor comp for premium vertical-SaaS healthcare. Private vertical leaders trade a revenue-multiple range depending on growth and gross-margin profile.
Payer-tech and digital health enablement:Wide range. Strategically valuable assets (prior-auth automation, claims-edit AI) trade a revenue-multiple range. Generic engagement tools and care-management point solutions trade a revenue-multiple range. Buyer concentration risk is the killer here — if a percent-of-revenue figure comes from two payers, the multiple compresses fast.
What Buyers Actually Diligence
Customer concentration in payer or provider.Healthcare IT companies routinely have one or two anchor customers driving 30%+ of revenue. Buyers underwrite this aggressively — they want to see contract length, renewal terms, and the operational depth of the integration. Concentrated revenue with multi-year terms and deep workflow integration is fine. Concentrated revenue on month-to-month contracts kills deals.
Compliance moat.HIPAA is table stakes. SOC 2 Type II is the institutional minimum. HITRUST CSF certification is what separates the premium tier — payers and large health systems will not buy without it, so HITRUST is genuine pricing power. Buyers will pay up for it because re-certifying a target post-close is a 12-18 month exercise.
Net revenue retention. The bar for a premium multiple is 110%+ NRR. The best vertical SaaS companies in healthcare IT (Veeva-style) run 115-125%. Below 100% NRR and buyers question the underlying product fit; the multiple compresses 2-4 turns.
Implementation revenue mix.Healthcare IT has historically been heavy on services revenue (implementation, customization, integration). Buyers strip services revenue out of the multiple calculation — they only pay SaaS multiples on subscription revenue. A company with 60% subscription / 40% services trades materially worse than a 90% subscription company at the same total revenue.
Interoperability and FHIR maturity. Post-21st Century Cures Act, the ability to support FHIR APIs, USCDI data classes, and bulk-data exports is increasingly diligenced. Companies architected on legacy HL7-only integration are seeing buyer pushback.
The Numbers from Our Database
We've tracked 483 healthcare-IT transactions, 321 of them in the last few years. The recent-period median earnings multiple sits at 17.3x with the P25-P75 range running 12.4-21.5x. On revenue, recent median is 4.4x with P25-P75 of 2.5-7.5x. The size brackets matter enormously: sub-$25M deals trade platform-tier earnings multiples, mid-market ($25-100M) trades 8-11x, and over-$500M deals trade platform-tier earnings multiples — that gap reflects scale, distribution, and category leadership premium more than fundamental quality differences.
Active Buyers in Healthcare IT
Strategic acquirers: Oracle Health (post-Cerner), UnitedHealth / Optum, Veeva, Waystar, Olive (now restructuring), Greenway, athenahealth, and increasingly Microsoft Cloud for Healthcare. Financial buyers: Bain Capital, Veritas, Vista Equity, Thoma Bravo, KKR, Kohlberg, TPG, and growth-stage investors like General Atlantic, ICONIQ, and Insight Partners. The pace of PE roll-ups in care coordination, prior-auth automation, and RCM is the highest I've seen in a decade.